Molecular Diagnostics Market

Molecular Diagnostics Market Size, Growth by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) - Global Forecasts to 2027

Report Code: MD 2521 May, 2022, by marketsandmarkets.com

The global Molecular Diagnostics Market boasts a total value of $23.2 billion in 2022 and is Projected to register a growth rate of 5.4% to reach a value of $30.2 billion by 2027. In the past several years, the development and application of molecular diagnostic techniques have initiated a revolution in diagnosing and monitoring infectious diseases. Due to the high prevalence of infectious diseases, the demand for molecular diagnostic products and services is expected to increase in the coming years, which, in turn, will drive market growth.

Molecular Diagnostics Market Size

To know about the assumptions considered for the study, Request for Free Sample Report

Molecular Diagnostics Market Dynamics

Growth Drivers: Rising focus on R&D and growing funding in molecular diagnostics

Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the molecular diagnostics market. For instance, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, with a USD-200-million budget, was announced in August 2020. This initiative aimed to accelerate the development, commercialization, and implementation of technologies for COVID-19 testing. Additionally, in 2019, the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US NIH, initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to support a broad portfolio of influenza research activities, including the development of vaccines, diagnostics, and therapeutics against seasonal and pandemic influenza. NIAID announced funds worth USD 51 million for CIVICs. Under the CIVICs program, investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with the H1N1 influenza virus or H3N2 influenza viruses to check for vaccine effectiveness. As diagnostic testing is an integral part of infection control, the global market is expected to gain momentum in the near future. Such examples of funding and government initiatives are expected to support the growth of the market.

Growth Opportunities: Growth opportunities in emerging countries

As markets in the US and Europe are maturing, most players are shifting their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructures in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of molecular diagnostics.

Restraints: Unfavorable reimbursement scenario

According to MedPAC (Medicare Payment Advisory Commission), medical testing has seen a 40% decline in reimbursement over the last 40 years. This decline and additional budgetary concerns among healthcare systems will be a major obstacle to implementing novel diagnostic techniques in clinical laboratories.

The Centers for Medicare & Medicaid Services (CMS) reduced the Medicare reimbursement rate for COVID-19 tests based on high-throughput technology to USD 75 unless labs can process results in under two days. Medicare does not currently provide genetic testing coverage for individuals without a personal history of cancer (Source: American Society of Clinical Oncology). These factors are expected to affect the US molecular testing market adversely.

Challenges: Operational barriers

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory spaces also need to be reconfigured to conduct specific molecular diagnostic tests used for pathogen detection to avoid cross-contamination and ensure efficient time management. This results in considerable cost escalations in maintaining and operating advanced molecular diagnostic instruments, particularly those capable of handling a single sample type.

Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced molecular diagnostic products has hindered their overall adoption, particularly in emerging markets.

Molecular Diagnostics Market Ecosystem

Molecular Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Reagents & kits segment to dominate the molecular diagnostics market

Reagents are essential components of all diagnostic analyses and generate accurate and precise test results. This is the largest and fastest-growing product segment in the global market. Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits.

PoC tests segment is expected to have the highest CAGR during the forecast period

One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as faster diagnosis are the major factors driving the demand for PoC tests.

Polymerase chain reaction segment to dominate the molecular diagnostics market

Polymerase chain reaction (PCR) is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). The development of portable real-time PCR machines and assays for point-of-care (PoC) infectious disease diagnostics and cancer diagnostics is expected to propel the growth of the PCR market. However, amplification-based target enrichment, such as PCR, is susceptible to allele drop-out, resulting in false negatives. This is a drawback for PCR, resulting in the growth of other technologies such as probe-based enrichment methods.

Asia Pacific is expected to be the fastest growing region during the forecast period.

Low infrastructure & treatment costs and the availability of highly educated physicians have driven medical tourists to APAC countries. This is a major factor driving the growth of the molecular diagnostics market in this region. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

However, factors such as the reluctance of healthcare professionals to adopt advanced diagnostic technologies due to budget constraints and pricing pressures faced by prominent product manufacturers are expected to restrain the market growth during the forecast period.

Molecular Diagnostics Market by Region

Molecular Diagnostics Market Key Players

The key players in global market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Abbott Laboratories (US).

Molecular Diagnostics Market Report Scope

Report Metric

Details

Market Revenue in 2022

$ 23.2 billion

Estimated Value by 2027

$ 30.2 billion

Growth Rate

Poised to grow at a CAGR of 5.4%

Largest Share Segments

  • Reagents & kits
  • PoC tests
  • Polymerase chain reaction

Market Report Segmentation

Product & Service, Test Type, Technology, Application, End User And Regional

Growth Drivers

  • Rising focus on R&D and growing funding in molecular diagnostics

Growth Opportunities

  • Growth opportunities in emerging countries

Geographies covered

North America, Europe, APAC, MEA, and Latin America

This report categorizes the global molecular diagnostics market into the following segments and subsegments:

By Product & Service

  • Reagents & Kits
  • Instruments
  • Services & Software

By Test Type

  • Lab Tests
  • PoC Tests

By Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • DNA Sequencing & Next- generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • DNA Microarrays
  • Other Technologies

By Application

  • Infectious Disease Diagnostics
    • COVID-19
    • Hepatitis
    • HIV
    • CT/NG
    • HAI
    • HPV
    • Tuberculosis
    • Influenza
    • Other Infectious Diseases
  • Oncology Testing
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Other Cancers
  • Genetic Testing
  • Other Applications

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments:

  • In September 2021, F. Hoffmann-La Roche Ltd. (Switzerland) announced the acquisition of TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases.
  • In June 2021, QIAGEN N.V.(Netherlands) partnered with Verogen (US) to broaden its portfolio in NGS technologies.
  • In June 2021, Hologic, Inc. (US) acquired Mobidiag Oy (Finland), an innovator in acute care molecular diagnostic testing. This acquisition will aid in expanding Hologic’s molecular diagnostics product portfolio.
  • In November 2020, Hologic, Inc. (US) received additional FDA approval for the AptimaHIV-1 Quant Dx Assay for use as an aid in the diagnosis of HIV infection.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 36)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
    1.3 MARKETS COVERED
           1.3.1 MOLECULAR DIAGNOSTICS : MARKET
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 42)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                               FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                               FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 LIMITATIONS
    2.8 GROWTH RATE ASSUMPTIONS
    2.9 RISK ASSESSMENT
           2.9.1 RISK ASSESSMENT: MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 55)
    FIGURE 8 MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 60)
    4.1 MARKET OVERVIEW
           FIGURE 14 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
    4.2 MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027
           FIGURE 15 REAGENTS & KITS WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.3 MARKET, BY TEST TYPE, 2022 VS. 2027
           FIGURE 16 THE LAB TESTS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.4 MARKET, BY TECHNOLOGY, 2022 VS. 2027
           FIGURE 17 THE PCR SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.5 MARKET, BY APPLICATION, 2022 VS. 2027
           FIGURE 18 THE INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.6 MARKET, BY END USER, 2022 VS. 2027
           FIGURE 19 THE DIAGNOSTIC LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.7 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 64)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer
                               TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
                               TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
                    5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics
                    5.2.1.3 Growing awareness of early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in molecular diagnostics
                    5.2.1.5 Increasing use of PoC diagnostic tests
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
                    5.2.2.2 High cost of instruments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing significance of companion diagnostics
                    5.2.3.2 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape
                    5.2.4.2 Operational barriers
                    5.2.4.3 Introduction of alternative technologies
           5.2.5 IMPACT OF COVID-19 ON THE MOLECULAR DIAGNOSTICS MARKET
    5.3 PRICING ANALYSIS
           TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
    5.4 PATENT ANALYSIS
           FIGURE 22 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 23 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS
           FIGURE 24 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET MAP
           FIGURE 25 MARKET: ECOSYSTEM/MARKET MAP
           5.7.1 MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS
           TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REGULATORY LANDSCAPE
           TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
                    TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                    5.9.3.3 India
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
                    5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
    5.11 TECHNOLOGY ANALYSIS
    5.12 KEY CONFERENCES & EVENTS IN 2022–2023
                    TABLE 10 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           5.13.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
                    FIGURE 26 REVENUE SHIFT IN THE MOLECULAR DIAGNOSTICS MARKET
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA
           5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
                    FIGURE 27 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
                    TABLE 11 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER (%)
           5.14.2 BUYING CRITERIA
                    FIGURE 28 KEY BUYING CRITERIA, BY END USER
                    TABLE 12 KEY BUYING CRITERIA, BY END USER
    5.15 CASE STUDIES
                    FIGURE 29 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 92)
    6.1 INTRODUCTION
           TABLE 13 MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
           TABLE 14 PRICES OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
    6.2 REAGENTS & KITS
           6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS—A KEY FACTOR PROPELLING MARKET GROWTH
                    TABLE 15 MOLECULAR DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST THE DEMAND FOR MOLECULAR DIAGNOSTIC INSTRUMENTS
                    TABLE 16 KEY INSTRUMENTS AVAILABLE IN THE MARKET
                    TABLE 17 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.4 SERVICES & SOFTWARE
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH IN THIS MARKET SEGMENT
                    TABLE 18 MOLECULAR DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 98)
    7.1 INTRODUCTION
           TABLE 19 MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)
    7.2 LAB TESTS
           7.2.1 HIGH BURDEN OF COVID-19 TO DRIVE MARKET GROWTH
                    TABLE 20 MARKET FOR LAB TESTS, BY REGION, 2020–2027 (USD MILLION)
    7.3 POC TESTS
           7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENTAL GROWTH IN THE COMING YEARS
                    TABLE 21 MARKET FOR POC TESTS, BY REGION, 2020–2027 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 102)
    8.1 INTRODUCTION
           8.1.1 PRIMARY NOTES
                    8.1.1.1 Key industry insights
                               TABLE 22 MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 POLYMERASE CHAIN REACTION (PCR)
           8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS MAKES THIS THE LARGEST MARKET SEGMENT
                    TABLE 23 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
    8.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
           8.3.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
                    TABLE 24 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
    8.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
           8.4.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL GROWTH IN THIS MARKET SEGMENT
                    TABLE 25 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
    8.5 IN SITU HYBRIDIZATION (ISH)
           8.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS— A KEY FACTOR DRIVING GROWTH
                    TABLE 26 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2020–2027 (USD MILLION)
    8.6 DNA MICROARRAYS
           8.6.1 INTRODUCTION OF DNA MICROARRAYS HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
                    TABLE 27 MARKET FOR DNA MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)
    8.7 OTHER TECHNOLOGIES
           TABLE 28 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 111)
    9.1 INTRODUCTION
           TABLE 29 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    9.2 INFECTIOUS DISEASE DIAGNOSTICS
           TABLE 30 MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
           TABLE 31 MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
           9.2.1 COVID-19
                    9.2.1.1 Growing burden of COVID-19 is a key factor driving market growth
                               TABLE 32 DISTRIBUTION OF TOTAL NUMBER OF CASES, BY COUNTRY
                               TABLE 33 MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 34 MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.2 HEPATITIS
                    9.2.2.1 Increasing adoption of advanced technologies for the diagnosis of hepatitis B to drive growth in this segment
                               TABLE 35 MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 36 MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.3 HIV
                    9.2.3.1 High global prevalence of HIV will drive the need for molecular diagnostic tests
                               TABLE 37 MARKET FOR HIV TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 38 MARKET FOR HIV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.4 HAI
                    9.2.4.1 Rising burden of MRSA infections and the increasing adoption of technologically advanced HAI diagnostic tests will likely drive market growth
                               TABLE 39 MARKET FOR HAI TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 40 MARKET FOR HAI TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.5 CT/NG
                    9.2.5.1 CT/NG infections are the most common STDs worldwide—a key factor driving market growth
                               TABLE 41 MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 42 MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.6 HPV
                    9.2.6.1 Technological advancements such as rapid HPV diagnostics drive growth in this segment
                               TABLE 43 MARKET FOR HPV TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 44 MARKET FOR HPV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.7 TUBERCULOSIS
                    9.2.7.1 Increasing burden of TB globally to propel the demand for MDx tests
                               TABLE 45 MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 46 MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.8 INFLUENZA
                    9.2.8.1 Rising focus on containing the spread of influenza to propel growth in this segment
                               TABLE 47 MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 48 MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (MILLION TESTS)
           9.2.9 OTHER INFECTIOUS DISEASES
                    TABLE 49 MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
    9.3 ONCOLOGY TESTING
           TABLE 50 MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
           TABLE 51 MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
           9.3.1 BREAST CANCER
                    9.3.1.1 Increasing prevalence of breast cancer is a key driver for market growth
                               TABLE 52 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 53 MOLECULAR DIAGNOSTIC MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.3.2 COLORECTAL CANCER
                    9.3.2.1 Rising focus on the development of companion diagnostic assays for colorectal cancer drives market growth
                               TABLE 54 MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.3.3 LUNG CANCER
                    9.3.3.1 Increasing research for lung cancer biomarkers to drive market growth
                               TABLE 55 MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.3.4 PROSTATE CANCER
                    9.3.4.1 Advancements in genomic technologies for the development of new biomarkers will drive the market growth
                               TABLE 56 MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
           9.3.5 OTHER CANCERS
                    TABLE 57 GLOBAL CANCER INCIDENCE, 2020
                    TABLE 58 MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
    9.4 GENETIC TESTING
           9.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 59 MARKET FOR GENETIC TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
    9.5 OTHER APPLICATIONS
           TABLE 60 MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 133)
     10.1 INTRODUCTION
               TABLE 61 MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.2 DIAGNOSTIC LABORATORIES
             10.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO DRIVE MARKET GROWTH
                       TABLE 62 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
     10.3 HOSPITALS & CLINICS
             10.3.1 INCREASING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS TO DRIVE THE GROWTH OF THIS SEGMENT
                       TABLE 63 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
     10.4 OTHER END USERS
               TABLE 64 MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

11 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 138)
     11.1 INTRODUCTION
               TABLE 65 MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA
               FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
               TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 67 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
               TABLE 68 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 69 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 70 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 71 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 72 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.1 US
                       11.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market growth in the US
                                   TABLE 73 US: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 74 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 75 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 76 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 77 US: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 78 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                       11.2.2.1 Availability of funding for genomics research makes Canada a sizeable market for molecular diagnostics
                                   TABLE 79 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 80 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 81 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 82 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 83 CANADA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 84 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.3 EUROPE
               TABLE 85 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 86 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
               TABLE 87 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 88 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 89 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 90 EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 91 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                       11.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
                                   TABLE 92 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 93 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 94 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 95 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 96 GERMANY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 97 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.2 UK
                       11.3.2.1 Growing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
                                   TABLE 98 UK: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 99 UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 100 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 101 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 102 UK: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 103 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.3 FRANCE
                       11.3.3.1 Rising R&D expenditure in France to drive market growth
                                   TABLE 104 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 105 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 106 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 107 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 108 FRANCE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 109 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                       11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
                                   TABLE 110 ITALY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 111 ITALY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 112 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 113 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 114 ITALY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 115 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.5 RUSSIA
                       11.3.5.1 Increasing access to quality healthcare will support market growth in Russia
                                   TABLE 116 RUSSIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 117 RUSSIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 118 RUSSIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 119 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 120 RUSSIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 121 RUSSIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.6 SPAIN
                       11.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
                                   TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 123 SPAIN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 124 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 125 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 126 SPAIN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 127 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.3.7 REST OF EUROPE
                       TABLE 128 ROE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                       TABLE 129 ROE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                       TABLE 130 ROE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                       TABLE 131 ROE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 132 ROE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 133 ROE: MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.4 ASIA PACIFIC
               FIGURE 31 APAC: MARKET SNAPSHOT
               TABLE 134 APAC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 135 APAC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
               TABLE 136 APAC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 137 APAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 138 APAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 139 APAC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 140 APAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.1 CHINA
                       11.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
                                   TABLE 141 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 142 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 143 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 144 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 145 CHINA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 146 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.2 JAPAN
                       11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                   TABLE 147 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 148 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 149 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 150 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 151 JAPAN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 152 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                       11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
                                   TABLE 153 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 154 INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 155 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 156 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 157 INDIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 158 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.4 AUSTRALIA
                       11.4.4.1 High prevalence of infectious diseases makes Australia a relatively large market in the APAC
                                   TABLE 159 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 160 AUSTRALIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 161 AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 162 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 163 AUSTRALIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 164 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                       TABLE 165 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                       TABLE 166 ROAPAC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                       TABLE 167 ROAPAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                       TABLE 168 ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 169 ROAPAC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 170 ROAPAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA
               TABLE 171 LATIN AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
               TABLE 172 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
               TABLE 173 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 174 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 175 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 176 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 177 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.1 BRAZIL
                       11.5.1.1 Improving healthcare infrastructure to drive the growth of the molecular diagnostics market in Brazil
                                   TABLE 178 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 179 BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 180 BRAZIL: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 181 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 182 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 183 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.2 MEXICO
                       11.5.2.1 Improving accessibility and affordability of healthcare services in Mexico makes it a favorable market for molecular diagnostics
                                   TABLE 184 MEXICO: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                   TABLE 185 MEXICO: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                   TABLE 186 MEXICO: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                   TABLE 187 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 188 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                                   TABLE 189 MEXICO: MARKET, BY END USER, 2020–2027 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                       TABLE 190 ROLATAM: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                       TABLE 191 ROLATAM: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                       TABLE 192 ROLATAM: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                       TABLE 193 ROLATAM: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 194 ROLATAM: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
                       TABLE 195 ROLATAM: MARKET, BY END USER, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
               TABLE 196 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
               TABLE 197 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
               TABLE 198 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
               TABLE 199 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 200 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
               TABLE 201 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 215)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE GLOBAL MARKET
                       TABLE 202 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
               FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
     12.4 MARKET SHARE ANALYSIS
             12.4.1 MARKET
                       FIGURE 33 MARKET SHARE, BY KEY PLAYER (2021)
                       TABLE 203 MARKET: DEGREE OF COMPETITION
             12.4.2 MARKET SHARE & RANKING ANALYSIS, BY TECHNOLOGY
                       12.4.2.1 Polymerase chain reaction (PCR)
                                   FIGURE 34 GLOBAL MARKET SHARE FOR PCR, BY KEY PLAYER (2021)
                       12.4.2.2 DNA sequencing and NGS
                                   FIGURE 35 GLOBAL MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2021)
                       12.4.2.3 Isothermal nucleic acid amplification technology (INAAT)
                                   TABLE 204 GLOBAL MARKET RANKING FOR INAAT, BY KEY PLAYER, 2021
                       12.4.2.4 In situ hybridization (ISH)
                                   TABLE 205 GLOBAL MARKET RANKING FOR ISH, BY KEY PLAYER, 2021
             12.4.3 MARKET RANKING ANALYSIS, BY APPLICATION
                       12.4.3.1 Infectious diseases
                                   TABLE 206 GLOBAL MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2021
                       12.4.3.2 COVID-19
                                   TABLE 207 GLOBAL MARKET RANKING FOR COVID-19, BY KEY PLAYER, 2021
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 LIST OF EVALUATED VENDORS
             12.5.2 STARS
             12.5.3 EMERGING LEADERS
             12.5.4 PERVASIVE PLAYERS
             12.5.5 PARTICIPANTS
                       FIGURE 36 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
     12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                       FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
     12.7 COMPETITIVE BENCHMARKING
             12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                       FIGURE 38 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
                       TABLE 208 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
                       TABLE 209 COMPANY PRODUCT & SERVICE FOOTPRINT
                       TABLE 210 COMPANY REGIONAL FOOTPRINT
                       TABLE 211 GLOBAL MARKET: DETAILED LIST OF KEY START-UPS/SMES
     12.8 COMPETITIVE SCENARIO
             12.8.1 PRODUCT LAUNCHES
                       TABLE 212 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
             12.8.2 DEALS
                       TABLE 213 KEY DEALS

13 COMPANY PROFILES (Page No. - 230)
     13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 F. HOFFMANN-LA ROCHE LTD
                       TABLE 214 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                       FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             13.1.2 HOLOGIC, INC.
                       TABLE 215 HOLOGIC, INC.: BUSINESS OVERVIEW
                       FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.3 PERKINELMER, INC.
                       TABLE 216 PERKINELMER, INC.: BUSINESS OVERVIEW
                       FIGURE 41 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
             13.1.4 ABBOTT LABORATORIES
                       TABLE 217 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                       FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             13.1.5 THERMO FISHER SCIENTIFIC, INC.
                       TABLE 218 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                       FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             13.1.6 QIAGEN N.V.
                       TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW
                       FIGURE 44 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             13.1.7 SIEMENS HEALTHINEERS AG
                       TABLE 220 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                       FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
             13.1.8 BIOMÉRIEUX SA
                       TABLE 221 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                       FIGURE 46 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             13.1.9 MYRIAD GENETICS, INC.
                       TABLE 222 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
                       FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
             13.1.10 DANAHER CORPORATION
                       TABLE 223 DANAHER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS
             13.2.1 ILLUMINA, INC.
                       TABLE 224 ILLUMINA, INC.: COMPANY OVERVIEW
             13.2.2 BECTON, DICKINSON AND COMPANY
                       TABLE 225 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
             13.2.3 GRIFOLS, S.A.
                       TABLE 226 GRIFOLS, S.A.: COMPANY OVERVIEW
             13.2.4 QUIDEL CORPORATION
                       TABLE 227 QUIDEL CORPORATION: COMPANY OVERVIEW
             13.2.5 AGILENT TECHNOLOGIES, INC.
                       TABLE 228 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
             13.2.6 DIASORIN S.P.A.
                       TABLE 229 DIASORIN S.P.A.: COMPANY OVERVIEW
             13.2.7 EXACT SCIENCES CORPORATION
                       TABLE 230 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
             13.2.8 GENETIC SIGNATURES
                       TABLE 231 GENETIC SIGNATURES: COMPANY OVERVIEW
             13.2.9 MDXHEALTH
                       TABLE 232 MDXHEALTH: COMPANY OVERVIEW
             13.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
                       TABLE 233 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY OVERVIEW
             13.2.11 BIOCARTIS NV
                       TABLE 234 BIOCARTIS NV: COMPANY OVERVIEW
             13.2.12 TBG DIAGNOSTICS LIMITED
                       TABLE 235 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
             13.2.13 VELA DIAGNOSTICS
                       TABLE 236 VELA DIAGNOSTICS: COMPANY OVERVIEW
             13.2.14 AMOY DIAGNOSTICS CO., LTD.
                       TABLE 237 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
             13.2.15 ELITECHGROUP
                       TABLE 238 ELITECHGROUP: COMPANY OVERVIEW
             13.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
                       TABLE 239 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
             13.2.17 SAVYON DIAGNOSTICS
                       TABLE 240 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
             13.2.18 ABACUS DIAGNOSTICA OY
                       TABLE 241 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
             13.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
                       TABLE 242 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW

14 APPENDIX (Page No. - 294)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Rotator Cuff Injury Treatment  Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Molecular Diagnostics Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Market Size: Top-Down Approach

Rotator Cuff Injury Treatment  Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global molecular diagnostics market, by product & service, test type, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Molecular diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional five company profiles of players operating in the molecular diagnostics market.
Report Code
MD 2521
Published ON
May, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback